Next Article in Journal
Teratogenicity of Ochratoxin A and the Degradation Product, Ochratoxin α, in the Zebrafish (Danio rerio) Embryo Model of Vertebrate Development
Previous Article in Journal
A New Member of Gamma-Conotoxin Family Isolated from Conus princeps Displays a Novel Molecular Target
Previous Article in Special Issue
Conotoxins That Could Provide Analgesia through Voltage Gated Sodium Channel Inhibition
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessArticle
Toxins 2016, 8(2), 38; doi:10.3390/toxins8020038

Apoptosis Activation in Human Lung Cancer Cell Lines by a Novel Synthetic Peptide Derived from Conus californicus Venom

1
Biomedical Innovation Department, Scientific Research and High Education Center of Ensenada (CICESE), Carretera Ensenada-Tijuana No 3918 Fracc, Zona Playitas Ensenada C.P. 22860, Baja California, Mexico
2
Cancer Center, Stanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
3
International Centre for Genetic Engineering and Biotechnology, Padriciano 99, 34149 Trieste, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Macdonald Christie
Received: 28 November 2015 / Revised: 26 January 2016 / Accepted: 28 January 2016 / Published: 5 February 2016
(This article belongs to the Special Issue Conotoxins: Novel Pharmacologies for Nervous System Disorders)
View Full-Text   |   Download PDF [3925 KB, uploaded 5 February 2016]   |  

Abstract

Lung cancer is one of the most common types of cancer in men and women and a leading cause of death worldwide resulting in more than one million deaths per year. The venom of marine snails Conus contains up to 200 pharmacologically active compounds that target several receptors in the cell membrane. Due to their diversity and specific binding properties, Conus toxins hold great potential as source of new drugs against cancer. We analyzed the cytotoxic effect of a 17-amino acid synthetic peptide (s-cal14.1a) that is based on a native toxin (cal14.1a) isolated from the sea snail Conus californicus. Cytotoxicity studies in four lung cancer cell lines were complemented with measurement of gene expression of apoptosis-related proteins Bcl-2, BAX and the pro-survival proteins NFκB-1 and COX-2, as well as quantification of caspase activity. Our results showed that H1299 and H1437 cell lines treated with s-call4.1a had decreased cell viability, activated caspases, and reduced expression of the pro-survival protein NFκB-1. To our knowledge, this is the first report describing activation of apoptosis in human lung cancer cell lines by s-cal14.1a and we offer insight into the possible mechanism of action. View Full-Text
Keywords: lung cancer; synthetic peptide; apoptotic-related genes; caspase-3 and -7; apoptosis; pathway lung cancer; synthetic peptide; apoptotic-related genes; caspase-3 and -7; apoptosis; pathway
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Oroz-Parra, I.; Navarro, M.; Cervantes-Luevano, K.E.; Álvarez-Delgado, C.; Salvesen, G.; Sanchez-Campos, L.N.; Licea-Navarro, A.F. Apoptosis Activation in Human Lung Cancer Cell Lines by a Novel Synthetic Peptide Derived from Conus californicus Venom. Toxins 2016, 8, 38.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top